Figure 5.

Intraperitoneal injection of Bay K8644 mitigates osteoporosis symptom of Zmpste24−/− mice. (a) The scheme for intraperitoneal injection and subsequent examination were shown. (b) After intraperitoneal injection for 5 days, BMMSCs from DMSO‐treated and Bay K8644‐treated Zmpste24−/− mice were isolated, and intracellular calcium currents were tested by laser confocal microscopy (n = 7). (c) After intraperitoneal injection for 5 days, BMMSCs from DMSO‐treated and Bay K8644‐treated Zmpste24−/− mice were isolated, and intracellular calcium concentrations were tested by flow cytometry assay (n = 7). (d) After intraperitoneal injection for 2 months, bone masses of DMSO‐treated wild‐type, DMSO‐treated Zmpste24−/−, and Bay K8644‐treated Zmpste24−/− groups were tested by micro‐CT (n = 6, 7 and 7). The “interesting zone” was highlighted. (e–g) BMD, BV/TV, and Tb.N were analyzed with the micview software (n = 6, 7 and 7). (h) After intraperitoneal injection for 2 months, bone formations of DMSO‐treated wild‐type, DMSO‐treated Zmpste24−/−, and Bay K8644‐treated Zmpste24−/− groups were examined by double‐calcein labeling (n = 6, 7 and 7). Scale bar, 25 um. (i) Mineral apposition rate (MAR) was analyzed by Image J under fluorescence microscope. Data are shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, which was determined by unpaired two‐tailed Student's t test